CA
NZ
UK
AU
IND
US
Zenas BioPharma (NASDAQ:ZBIO) rose USD 1.55 to USD 28.43 on October 7, 2026, published market data show. That is about 5.8% by simple arithmetic, while the headline says 5.5%. The company release of October 6, 2026 announced a virtual R&D event on October 27 …
● Caribou Biosciences tumbled to about $0.61 after hours.
Apimeds Pharmaceuticals (NYSE American:APUS) soared on Tuesday, October 6, trading at about $7.00, with its market value put at about $6.9 million. No company announcement explaining the move was found, and no press release, filing or clinical update tied to the session turned up …
ArriVent BioPharma (NASDAQ:AVBP) plunged on Tuesday, October 6, trading around $15.59, which placed it among the session's biggest health-care decliners. No reason was given for the drop, and no company announcement explaining the move was found.
CG Oncology (NASDAQ:CGON) slid on Tuesday, October 6, trading around $63.94. No new company-specific news was found to explain the move. The decline came as smaller health-care stocks broadly lost ground.
Caribou Biosciences (NASDAQ:CRBU) plunged in extended trading on Tuesday, October 6, falling to about $0.61 a share, with its market value put at about $127.5 million. The move left the gene-editing company as one of the sharpest decliners among Russell 2000 names after the …
Ginkgo Bioworks (NYSE:DNA) soared on Tuesday, October 6, trading around $17.64, which placed it among the day's notable gainers. No reason for the move was given, and no company announcement explaining it was found.
GRAIL (NASDAQ:GRAL) slid on Tuesday, October 6, trading around $143.23. No company-specific news was found to explain the move. Instead, the cancer-detection company fell alongside a broad pullback in diagnostics and life-science tools stocks.
Intellia Therapeutics (NASDAQ:NTLA) was in focus on Tuesday, October 6, after Barclays initiated coverage with an Underweight rating. That rating signals that the bank expects the shares to lag the group it measures them against. Launching coverage with a negative stance is less common …
Novavax (NASDAQ:NVAX) sank on Tuesday, October 6, ranking among the most-discussed decliners in the Russell 2000. The selling followed the World Health Organization's assessment that the risk from a pneumonic plague outbreak was low, according to live market coverage.
Please wait processing your request...